Chemo Mouthpiece prevents oral mucositis in patients

The device offers the first proactive solution to a common and painful side effect of chemotherapy.

U.S.-based Chemo Mouthpiece LLC is offering what it calls the first proactive device to prevent oral mucositis, a painful and often debilitating side effect of chemotherapy.

“Our product is a very innovative product, the first of its kind,” said Jeff Kalman, Director of International Business Development at Chemo Mouthpiece LLC, during Medical Taiwan 2025. “It is a single patient, multiple use device that is transportable… to reduce the incidence and the severity of one of the worst side effects of chemotherapy called oral mucositis.”

Kalman highlighted a key gap in current cancer care. “Currently, the standard of care… is to literally let them get oral mucositis and then try to fight,” he said. “There really is nothing that is proactive in the market… until now.”

The company’s main challenge now is awareness. “Most doctors have never even heard of it,” Kalman noted. “They never heard or realised that there is now a product… that can reduce the incidence and severity, and can be prescribed proactively.”

Chemo Mouthpiece has received breakthrough technology status in the U.S., and Kalman said global expansion efforts are underway.